EUVIMEDEUVIMED entdecken
Crossref

Tirzepatide, a dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β‐cells and hepatic steatosis in obese type 2 diabetic db/db mice

Yuichiro Iwamoto iD, Tomohiko Kimura iD, Kazunori Dan, Hideyuki Iwamoto, Junpei Sanada, Yoshiro Fushimi, Yukino Katakura, Masashi Shimoda iD, Yuki Yamasaki, Yuka Nogami, Yoshiko Shirakiya, Shuhei Nakanishi und 3 weitere

Diabetes, Obesity and Metabolism · 2024-12 · 26 (12) · 5982-5994

DOI: 10.1111/dom.15972 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 30.09.2024. Verfasst von Yuichiro Iwamoto und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan. Hauptthemen laut MEDLINE: Insulin-Secreting Cells, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptides. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Tirzepatide, a dual agonist of glucagon‐like peptide receptor and glucose‐dependent insulinotropic polypeptide receptor, is expected to exhibit high clinical efficacy in obese type 2 diabetic patients. We evaluated the effects of tirzepatide on pancreatic β‐cells and the liver, an insulin‐target organ, in a mouse model of obese type 2 diabetes mellitus. Materials and Methods Obese type 2 diabetic db/db mice (BKS.Cg−/+ Leprdb/+ Leprdb/Jcl*) were used in this study. Starting at 7 weeks of age, mice were treated with tirzepatide (30 nmol/kg, subcutaneous injection twice a week) or semaglutide (200 nmol/kg, subcutaneous injection twice a week). The control group received phosphate‐buffered saline (40–50 μL/subcutaneous injection twice a week). After 4 weeks of drug administration, pancreatic β‐cells and the liver were removed and examined.

Results

Compared to the control group, blood glucose and body weight were significantly reduced in the group that received either tirzepatide or semaglutide ( p < 0.001 and p < 0.05, respectively). Fasting insulin was significantly higher in the semaglutide and tirzepatide groups compared to the control group ( p < 0.001). β‐Cell mass and quality of insulin granules in β‐cells similarly increased in the semaglutide and tirzepatide groups compared to the control group ( p < 0.05 and p < 0.001, respectively). The fat staining area in the liver in oil red O staining and the liver–spleen ratio in computed tomography showed improvement only in the tirzepatide group ( p < 0.001 and p < 0.005, respectively). Liver macrophage M1/M2 ratio similarly improved with semaglutide and tirzepatide ( p < 0.05).

Conclusion

Tirzepatide and semaglutide exhibited similar potent glucose‐lowering effects. At concentrations used in the present experiments, tirzepatide exhibited more beneficial effects on β‐cell‐related gene expression, insulin granule count and glucose‐stimulated insulin secretion compared to semaglutide. In addition, tirzepatide exhibited a stronger favourable effect on hepatic fat deposition and improved inflammation in the liver. This is the first report showing that tirzepatide, a novel diabetes drug, exhibits a superior effect on pancreatic β‐cells and the liver of obese type 2 diabetic mice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin-Secreting CellsDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 ReceptorGlucagon-Like PeptidesBlood GlucoseGlucagon-Like Peptide-1 Receptor AgonistsAnimalsMiceMaleFatty LiverLiverHypoglycemic AgentsObesityMice, ObeseGlucagon-Like Peptide-2 ReceptorGastric Inhibitory PolypeptideTirzepatideSemaglutide

Stichwörter der Autor:innen

GIP receptorGLP‐1 receptorpancreatic β‐cellssteatosistype 2 diabetes mellitus

Substanzen

Glucagon-Like Peptide-1 ReceptorGlucagon-Like PeptidesBlood GlucoseHypoglycemic AgentsGlucagon-Like Peptide-2 ReceptorGastric Inhibitory PolypeptideTirzepatideGlucagon-Like Peptide-1 Receptor AgonistsSemaglutide

Autor:innen und Institutionen

  • Department of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan.

ORCID-Profile: Yuichiro Iwamoto, Tomohiko Kimura, Masashi Shimoda, Kohei Kaku

Zitieren

APA

Iwamoto, Y., Kimura, T., Dan, K., Iwamoto, H., Sanada, J., Fushimi, Y., Katakura, Y., Shimoda, M., Yamasaki, Y., Nogami, Y., Shirakiya, Y., Nakanishi, S., Mune, T., Kaku, K., & Kaneto, H. (2024). Tirzepatide, a dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β‐cells and hepatic steatosis in obese type 2 diabetic db/db mice. Diabetes, Obesity and Metabolism, 26(12), 5982-5994. https://doi.org/10.1111/dom.15972

Vancouver

Iwamoto Y, Kimura T, Dan K, Iwamoto H, Sanada J, Fushimi Y, et al. Tirzepatide, a dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β‐cells and hepatic steatosis in obese type 2 diabetic db/db mice. Diabetes, Obesity and Metabolism. 2024;26(12):5982-5994. doi:10.1111/dom.15972

BibTeX
@article{Iwamoto2024,
  author = {Iwamoto, Yuichiro and Kimura, Tomohiko and Dan, Kazunori and Iwamoto, Hideyuki and Sanada, Junpei and Fushimi, Yoshiro and Katakura, Yukino and Shimoda, Masashi and Yamasaki, Yuki and Nogami, Yuka and Shirakiya, Yoshiko and Nakanishi, Shuhei and Mune, Tomoatsu and Kaku, Kohei and Kaneto, Hideaki},
  title = {Tirzepatide, a dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β‐cells and hepatic steatosis in obese type 2 diabetic db/db mice},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  volume = {26},
  number = {12},
  pages = {5982--5994},
  doi = {10.1111/dom.15972}
}
Kostenlos starten →